about
Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells.Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism.The design, synthesis and antiviral evaluation of a series of 5-trimethylsilyl-1-beta-D-(arabinofuranosyl)uracil phosphoramidate ProTides.Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines.Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus.Virtual screening of acyclovir derivatives as potential antiviral agents: design, synthesis and biological evaluation of new acyclic nucleoside ProTides.Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives.Bicyclic nucleoside inhibitors of Varicella-Zoster virus: the effect of branching in the p-alkylphenyl side chain.Non-nucleoside structures retain full anti-HCMV potency of the dideoxy furanopyrimidine family.Synthesis, anti-HIV and cytostatic evaluation of 3'-deoxy-3'-fluorothymidine (FLT) pro-nucleotides.PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.Synthesis of an apionucleoside family and discovery of a prodrug with anti-HIV activity.Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides.Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase.Alkyloxyphenyl furano pyrimidines as potent and selective anti-VZV agents with enhanced water solubility.Synthesis and biological evaluation of purine 2'-fluoro-2'-deoxyriboside ProTides as anti-influenza virus agents.Halophenyl furanopyrimidines as potent and selective anti-VZV agents.Novel bicyclic furanopyrimidines with dual anti-VZV and -HCMV activity.Synthesis and antiviral evaluation of some 3'-fluoro bicyclic nucleoside analogues.Bicyclic anti-VZV nucleosides: thieno analogues bearing an alkylphenyl side chain have reduced antiviral activity.Design, Synthesis and Biological Evaluation of Novel Acyclovir ProTidesDesign, Synthesis and Evaluation of Novel Anti-VZV BCNAsDesign, Synthesis, and Biological Evaluation of Novel Fluoro Derivatives of BCNAThe Application of Phosphoramidate Protide Technology to Acyclovir confers Novel Anti-HIV InhibitionApplication of the Phosphoramidate Protide Approach to the Antiviral Drug RibavirinDesign, synthesis, and anti-HIV activity of 2′,3′-didehydro-2′,3′-dideoxyuridine (d4U), 2′,3′-dideoxyuridine (ddU) phosphoramidate ‘ProTide’ derivativesDesign, synthesis, and biological evaluation of C1–phosphonamidate analogues of 2-deoxy-d-ribose-1-phosphateSynthesis and Evaluation of Novel Acyclovir Phosphoramidates as Anti-HIV Agents92 Ara-A-5′-phenyl methoxy alaninyl phosphate as a prodrug of the adenine arabinoside -monophosphate: synthesis and anti viral evaluationPhosphoramidate derivatives of 2′,3′-didehydro-2′,3′-dideoxyadenosine [d4A] have markedly improved anti-HIV potency and selectivityPhosphoramidate derivatives of d4T with improved anti-HIV efficacy retain full activity in thymidine kinase-deficient cells
P50
Q37598750-C0E6C6BF-868F-409A-845E-2025720F1888Q39726060-07C3434E-D15D-482F-8EF9-37FEA8095BF4Q39727337-44EC0D26-88B8-4483-B184-EFEE8C2FD7D2Q40041877-A65251D1-7A86-4500-A09E-23FD00E26994Q40063433-D8651FD8-D866-4283-B1C8-756D6E2BFFA0Q40075273-C252C4E4-AB66-4178-AF43-593D8A325782Q40204688-204E3A35-0C4B-4D54-B082-BCBCDC11DE3AQ40408720-60D620EA-F879-404F-9733-55D44BA0F18BQ40472494-0E03FC83-5E26-45D1-BA24-555CCED18E68Q42223234-03F63AC1-E852-4BDB-B31E-FF359312E485Q42227867-B3CCA82E-55A8-41F8-B6D5-5AD285E91889Q42705746-A691EC49-EFF5-41BA-97C6-254B3B5CCFF4Q42731753-E8402190-133C-4D04-BDED-78B58C2B97ACQ43865580-F34A45CF-2A50-4C8C-8DFB-DBF4591264A6Q44142337-F33398D9-BF6B-467D-94D0-4CD098EF328CQ44290166-22C864A1-21F3-4387-879E-A8500498DC1BQ44604103-29E5616E-5C98-40A3-A9E8-32CB564FE89AQ44672445-9B33E6EA-7C7B-4EDA-BBAD-56BB5B305B3EQ44813577-2C5ACD15-D8D0-46C5-AF9E-70A5358626C8Q44861835-D9B66B36-1C3C-41B9-B7A6-8AC7F7F1A13CQ57241287-D0D72EBE-3A85-48D7-9379-57A8407E7338Q57241289-89BFACE8-D91A-46E1-9362-C52EA90FA8ADQ57266117-CD72AA38-48D1-4470-8FE9-356E3F7265F6Q57266120-86AE89EE-A25A-4704-9C31-995280589CDAQ57266127-250A2342-8415-44E5-A16C-C746D1B7198AQ57266136-99EE197D-70ED-4B37-AB0D-7F0B5E048CD1Q57637125-B26FB1FA-BDEB-4C12-B28D-FEF451405A04Q57637175-1D4A61C7-A003-482D-AD98-D3A429C2D813Q57637254-32A22846-452A-4DC5-B32C-445C5F37FFE4Q57637285-239976A7-8FBF-4444-AB95-BB354D97252FQ57637288-2E1E8880-B2D8-477D-9E6C-341E5F1E82F7
P50
name
Christopher McGuigan
@en
Christopher McGuigan
@nl
type
label
Christopher McGuigan
@en
Christopher McGuigan
@nl
prefLabel
Christopher McGuigan
@en
Christopher McGuigan
@nl